• Please log in or register to access this feature.

Research Article

You have full text access to this OnlineOpen article

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial

  1. Edward C. Keystone1,†,*,
  2. Arthur F. Kavanaugh2,†,
  3. John T. Sharp3,
  4. Hyman Tannenbaum4,
  5. Ye Hua5,‡,
  6. Leah S. Teoh5,
  7. Steven A. Fischkoff5,‡,
  8. Elliot K. Chartash5,‡

Article first published online: 6 MAY 2004

DOI: 10.1002/art.20217

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 50, Issue 5, pages 1400–1411, May 2004

Additional Information

How to Cite

Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A. and Chartash, E. K. (2004), Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis & Rheumatism, 50: 1400–1411. doi: 10.1002/art.20217

Author Information

  1. 1

    University of Toronto, Toronto, Ontario, Canada

  2. 2

    University of California, San Diego

  3. 3

    University of Washington School of Medicine, Seattle

  4. 4

    McGill University, Montreal, Quebec, Canada

  5. 5

    Abbott Laboratories, Parsippany, New Jersey

  1. †

    Drs. Keystone and Kavanaugh have served as consultants to Abbott Laboratories.

  2. ‡

    Drs. Hua, Fischkoff, and Chartash own stock in Abbott Laboratories.

*Mount Sinai Hospital, The Rebecca MacDonald Centre, 2nd Floor, Room 2-006, 60 Murray Street, Toronto, Ontario M5G 1X5, Canada

  1. †

    Drs. Keystone and Kavanaugh have served as consultants to Abbott Laboratories.

  2. ‡

    Drs. Hua, Fischkoff, and Chartash own stock in Abbott Laboratories.

Publication History

  1. Issue published online: 6 MAY 2004
  2. Article first published online: 6 MAY 2004
  3. Manuscript Accepted: 29 JAN 2004
  4. Manuscript Received: 17 APR 2003

Funded by

  • Abbott Laboratories, Abbott Park, Illinois

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (167K)

REFERENCES

  • 1
    Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358: 903–11.
  • 2
    Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16: 585–91.
  • 3
    Kremer JM. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years. Arthritis Rheum 1997; 40: 984–5.
    Direct Link:
  • 4
    Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907–16.
  • 5
    Salfeld J, Kaymakçalan Z, Tracey D, Roberts A, Kamen R. Generation of fully human anti-TNF antibody D2E7 [abstract]. Arthritis Rheum 1998; 41 Suppl 9: S57.
  • 6
    Barrera P, Joosten LA, den Broeder AA, van de Putte LB, van Riel PL, van den Berg WB. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF alpha in patients with rheumatoid arthritis. Ann Rheum Dis 2001; 60: 660–9.
  • 7
    Barrera P, van der Maas A, van Ede AE, Kiemeney BALM, Laan RFJM, van de Putte BA. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-α antibody compared with methotrexate in long-standing rheumatoid arthritis. Rheumatology (Oxford) 2002; 41: 430–9.
  • 8
    Den Broeder AA, Joosten LA, Saxne T, Heinegard D, Fenner H, Miltenburg AM, et al. Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 2002; 61: 311–8.
  • 9
    Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35–45.
    Direct Link:
  • 10
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
    Direct Link:
  • 11
    Van de Putte LBA, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PLCM, et al. Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003; 62: 1168–77.
  • 12
    Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis: correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971; 14: 706–20.
    Direct Link:
  • 13
    Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett M, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 1985; 28: 1326–35.
    Direct Link:
  • 14
    Plant MJ, Saklatvala J, Borg AA, Jones PW, Dawes PT. Measurement and prediction of radiological progression in early rheumatoid arthritis. J Rheumatol 1994; 21: 1808–13.
  • 15
    Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729–40.
    Direct Link:
  • 16
    Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982; 9: 789–93.
  • 17
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–83.
  • 18
    Goldsmith C, Boers M, Bombardier C, Tugwell P. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. J Rheumatol 1993; 20: 561–5.
  • 19
    Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43: 1478–87.
    Direct Link:
  • 20
    Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986; 319: 516–8.
  • 21
    Saklatvala J. Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986; 322: 547–9.
  • 22
    Scott DL, Pugner K, Kaarela K, Doyle DV, Wodil A, Holmes J. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 122–32.
  • 23
    Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001; 44: 2009–17.
    Direct Link:
  • 24
    Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy. Rheumatology (Oxford) 2003; 42: 617–21.
  • 25
    Singh G, Ramey DR, Rausch PL, Schettler JD. Serious infections in rheumatoid arthritis: relationship to immunosuppressive use [abstract]. Arthritis Rheum 1999; 42 Suppl 9: S242.
  • 26
    Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287–93.
    Direct Link:
  • 27
    Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 1238–44.
  • 28
    Lipsky PE, van der Heijde DM, St Clair EW. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 34: 1594–602.
  • 29
    KosaryCL, RiesLAG, MillerBA, HankeyBF, HarrasA, EdwardsBK, editors. SEER cancer statistics review, 1973–1992: tables and graphs. Bethesda, Maryland: US Department of Health and Human Services, Public Health Service, National Institutes of Health. DHHS publication no. (NIH)96-2789; 1995.
  • 30
    Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997; 47: 5–27.
    Direct Link:
  • 31
    American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 328–46.
    Direct Link:
View Full Article (HTML) Get PDF (167K)